Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Shin Nippon Biomedical Laboratories, Ltd. ( (JP:2395) ) has provided an announcement.
Shin Nippon Biomedical Laboratories has revised its full-year consolidated forecast for the fiscal year ending March 31, 2026, lowering projected revenue and operating profit but slightly increasing profit attributable to owners of the parent. Revenue is now expected to fall 7.7% below the previous forecast, mainly because nonclinical business revenues are being pushed into the following fiscal year due to delays in client compound supply and the expansion of several large-scale projects, even as orders in that segment hit a record quarterly high and are expected to support future performance. Operating profit is projected to drop 26.8% from the initial plan, reflecting the timing shift in nonclinical revenue and ¥1,241 million in second-half costs at U.S. subsidiary Satsuma Pharmaceuticals, partly offset by cost controls in the broader TR business, while ordinary profit is revised down less thanks to stronger-than-expected equity-method income from PPD-SNBL K.K. and net income is nudged up on lower taxes stemming from flexible management of NHP shipment volumes from Cambodia to Japan.
The most recent analyst rating on (JP:2395) stock is a Buy with a Yen1802.00 price target. To see the full list of analyst forecasts on Shin Nippon Biomedical Laboratories, Ltd. stock, see the JP:2395 Stock Forecast page.
More about Shin Nippon Biomedical Laboratories, Ltd.
Shin Nippon Biomedical Laboratories, Ltd. (SNBL), listed on the TSE Prime, operates in the biomedical and drug development support industry, with a core focus on nonclinical testing services and translational research (TR). The company serves pharmaceutical and biotech clients globally, including through its U.S. subsidiary Satsuma Pharmaceuticals, Inc. and its Cambodian subsidiary supplying non-human primates (NHPs) for research, positioning SNBL as a key contract research organization in preclinical development.
Average Trading Volume: 285,930
Technical Sentiment Signal: Buy
Current Market Cap: Yen68.07B
For an in-depth examination of 2395 stock, go to TipRanks’ Overview page.